Medicare AdvantageCoverageMedium impact
MA08.075i, Ramucirumab (Cyramza®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
May 27, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.075i for Ramucirumab (Cyramza®) has been reissued and will become effective May 27, 2026. This is a pharmacy-related policy update that may affect coverage or billing requirements for this cancer medication.
Action Required
Before May 27, 2026: Review the complete policy details at the provided URL to understand specific coverage changes for Ramucirumab (Cyramza®). Billing team should verify any new prior authorization requirements, documentation needs, or billing restrictions for Medicare Advantage patients receiving this medication.